Drugmakers Gain as Markets Digest Trump’s Proposed 100% Pharma Tariffs
Exemptions for U.S. plant construction and existing expansion plans temper immediate fallout, but uncertainty remains for smaller firms Shares of ...
Tag: LLY
Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial
Strong weight reduction overshadowed by concerns over side effects Viking Therapeutics (VKTX) shares plummeted nearly 45% on Tuesday after the ...
Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development
Partnership leverages artificial intelligence to accelerate discovery of next-generation treatments for obesity and cardiometabolic diseases Eli Lilly (LLY) has entered ...
Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock
Zepbound and Mounjaro Drive U.S. Sales, Yet Orforglipron Trial Results Raise Investor Concerns Eli Lilly (LLY) delivered a solid second-quarter ...
Novo Nordisk’s CagriSema Trial Results Shake Market Confidence
Disappointing Data Spurs $125 Billion Market Value Drop Novo Nordisk’s (NVO) ambitions in the competitive obesity drug market took a ...
